Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer

Tsuchihashi Kenji; Ito Mamoru; Moriwaki Toshikazu; Fukuoka Shota; Taniguchi Hiroya; Takashima Atsuo; Kumekawa Yosuke; Kajiwara Takeshi; Yamazaki Kentaro; Esaki Taito; Makiyama Akitaka; Denda Tadamichi; Satake Hironaga; Suto Takeshi; Sugimoto Naotoshi; Katsumata Kenji; Ishikawa Toshiaki; Kashiwada Tomomi; Oki Eiji; Komatsu Yoshito; Okuyama Hiroyuki; Sakai Daisuke; Ueno Hideki; Tamura Takao; Yamashita Kimihiro; Kishimoto Junji; Shimada Yasuhiro; Baba Eishi

首页> 外文期刊>Clinical colorectal cancer >Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer

【24h】

Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer

机译：改性格拉斯哥预测值对转移结直肠癌患者后期化疗预测值的作用

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The survival and safety of patients with metastatic colorectal cancer treated with trifluridine/tipiracil or regorafenib as later-line chemotherapy were retrospectively examined according to the modified Glasgow Prognostic Score (mGPS). Overall and progression-free survival were strongly correlated with mGPS in all patients. The frequency of adverse events was generally similar in each mGPS group.

机译：用Trifluridine / Tipiracil或Regorafenib处理的转移结直肠癌患者的存活和安全性根据改性的Glasgow预后评分（MGP）回顾性检查。总体和无进展的生存率与所有患者的MGP强烈相关。不良事件的频率在每个MGPS组中通常相似。

著录项

来源
《Clinical colorectal cancer 》 |2018年第4期| 共11页
作者
Tsuchihashi Kenji; Ito Mamoru; Moriwaki Toshikazu; Fukuoka Shota; Taniguchi Hiroya; Takashima Atsuo; Kumekawa Yosuke; Kajiwara Takeshi; Yamazaki Kentaro; Esaki Taito; Makiyama Akitaka; Denda Tadamichi; Satake Hironaga; Suto Takeshi; Sugimoto Naotoshi; Katsumata Kenji; Ishikawa Toshiaki; Kashiwada Tomomi; Oki Eiji; Komatsu Yoshito; Okuyama Hiroyuki; Sakai Daisuke; Ueno Hideki; Tamura Takao; Yamashita Kimihiro; Kishimoto Junji; Shimada Yasuhiro; Baba Eishi;
展开▼
作者单位

Kyushu Univ Grad Sch Med Sci Dept Med &

Biosyst Sci Fukuoka Fukuoka Japan;

Kyushu Univ Grad Sch Med Sci Dept Med &

Biosyst Sci Fukuoka Fukuoka Japan;

Univ Tsukuba Fac Med Div Gastroenterol Tsukuba Ibaraki Japan;

Natl Canc Ctr Hosp East Dept Gastrointestinal Oncol Kashiwa Chiba Japan;

Aichi Canc Ctr Hosp Dept Clin Oncol Chikusa Ku Nagoya Aichi Japan;

Natl Canc Ctr Gastrointestinal Med Oncol Div Chuo Ku Tokyo Japan;

Saitama Canc Ctr Dept Gastroenterol Ina Saitama Japan;

Natl Hosp Org Shikoku Canc Ctr Dept Gastrointestinal Med Oncol Minamiumemoto Machi Matsuyama;

Shizuoka Canc Ctr Div Gastrointestinal Oncol Nagaizumi Shizuoka Japan;

Natl Kyushu Canc Ctr Dept Gastrointestinal &

Med Oncol Minami Ku Fukuoka Fukuoka Japan;

Japan Community Healthcare Org Kyushu Hosp Dept Hematol Oncol Yahatanishi Ku Kitakyushu Fukuoka;

Chiba Canc Ctr Div Gastroenterol Chuo Ku Chiba Chiba Japan;

Kobe City Med Ctr Gen Hosp Dept Med Oncol Chuo Ku Kobe Hyogo Japan;

Yamagata Prefectural Cent Hosp Dept Gastroenterol Surg Yamagata Yamagata Japan;

Osaka Int Canc Inst Dept Med Oncol Chuo Ku Osaka Osaka Japan;

Tokyo Med Univ Dept Gastrointestinal &

Pediat Surg Shinjuku Ku Tokyo Japan;

Tokyo Med &

Dent Univ Grad Sch Med &

Dent Dept Specialized Surg Bunkyo Ku Tokyo Japan;

Saga Univ Fac Med Dept Internal Med Div Hematol Resp Med &

Oncol Saga Saga Japan;

Kyushu Univ Grad Sch Med Sci Dept Surg &

Sci Higashi Ku Fukuoka Fukuoka Japan;

Hokkaido Univ Hosp Canc Ctr Dept Canc Chemotherapy Kita Ku Sapporo Hokkaido Japan;

Kagawa Univ Fac Med Dept Clin Oncol Miki Kagawa Japan;

Osaka Univ Grad Sch Med Dept Frontier Sci Canc &

Chemotherapy Suita Osaka Japan;

Natl Def Med Coll Hosp Dept Surg Tokorozawa Saitama Japan;

Kindai Univ Fac Med Dept Med Oncol Osaka Osaka Japan;

Kobe Univ Grad Sch Med Dept Surg Div Gastrointestinal Surg Chuo Ku Kobe Hyogo Japan;

Kyushu Univ Hosp Ctr Clin &

Translat Res Fukuoka Fukuoka Japan;

Kochi Hlth Sci Ctr Clin Oncol Div Kochi Kochi Japan;

Kyushu Univ Fac Med Sci Dept Comprehens Clin Oncol Higashi Ku 3-1-1 Maidashi Fukuoka Fukuoka;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学 ;
关键词
Colon; Inflammation; Nutrition; Regorafenib; Trifluridine/tipiracil;

机译：结肠;炎症;营养;regorafenib;Trifluridine / Tipiracil;

相似文献

外文文献
中文文献
专利

1. Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer [J] . Tsuchihashi Kenji, Ito Mamoru, Moriwaki Toshikazu, Clinical colorectal cancer . 2018 ,第4期

机译：改性格拉斯哥预测值对转移结直肠癌患者后期化疗预测值的作用
2. A prognostic indicator of survival in metastatic colorectal cancer patients in the era of molecular-targeted agents: The modified glasgow prognostic score [J] . DreanicJ., DhoogeM., BrezaultC., Oncology: International Journal of Cancer Research and Treatment . 2014 ,第1期

机译：分子靶向药物时代转移性大肠癌患者生存的预后指标：改良的格拉斯哥预后评分
3. The impact of the Glasgow Prognostic Score on survival in second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation [J] . Seiichiro Mitani, Hiroya Taniguchi, Keiji Sugiyama, Therapeutic advances in medical oncology. . 2019 ,第11期

机译：格拉斯哥预后评分对BRAF V600E突变的转移性结直肠癌患者二线化疗生存率的影响
4. Isolation of Circulating Tumor Cells from Patients with Metastatic Colorectal Cancer Using Label-Free Microfluidic Technology for Enumeration and Detection of KRAS, BRAF, PIK3CA Mutation [C] . Haiyan Emily Liu, Evelyn Kidess-Sigal, Melanie Triboulet, International Molecular Medicine Tri-Conference. . 2016

机译：使用无标记微流体技术分离转移性结肠直肠癌患者的循环肿瘤细胞进行募准和检测KRA，BRAF，PIK3CA突变
5. Subgroup analysis based on prognostic and predictive gene signatures for adjuvant chemotherapy in early-stage non-small-cell lung cancer patients [D] . Pluta, Dustin. 2015

机译：基于预后和预测基因特征的亚组分析用于早期非小细胞肺癌患者的辅助化疗
6. Combination chemotherapy with TAS-102 plus bevacizumab in salvage-line treatment of metastatic colorectal cancer: A single-center retrospective study examining the prognostic value of the modified Glasgow Prognostic Score in salvage-line therapy of metastatic colorectal cancer [O] . Nobuhisa Matsuhashi, Takao Takahashi, Hironori Fujii, -1

机译：TAS-102联合贝伐单抗联合化疗在转移性结直肠癌抢救治疗中的单中心回顾性研究探讨改良的格拉斯哥预后评分在转移性结直肠癌抢救治疗中的预后价值
7. The impact of the Glasgow Prognostic Score on survival in second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation [O] . Seiichiro Mitani, Hiroya Taniguchi, Keiji Sugiyama, 2019

机译：Glasgow预后评分对BRAF v600E突变转移结直肠癌患者的二线化疗存活

Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer

摘要

著录项

相似文献

相关主题

期刊订阅